CSPC PHARMACEUT.GR. ADR4 Cash Flow Quality Index
CSPC PHARMACEUT.GR. ADR4 cash flow quality index. CSPC PHARMACEUT.GR. ADR4 (CVGU) has a Cash Flow Quality Index of 1.50x as of December 2025. Operating cash flow of €5.83 Billion exceeds net income of €3.88 Billion, indicating high earnings quality where cash backs reported profits. See CVGU financial flexibility score to measure the company's free cash flow as a share of total liabilities.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cash Flow Quality Index of CSPC PHARMACEUT.GR. ADR4 (2021–2025)
Cash flow quality index of CSPC PHARMACEUT.GR. ADR4 from 2021 to 2025. Historical Cash Flow Quality Index for CSPC PHARMACEUT.GR. ADR4 across 5 annual periods. Values consistently above 1.0x indicate high-quality earnings. Explore how well can CSPC PHARMACEUT.GR. ADR4 service its debt to assess how comfortably operating cash covers total debt obligations.
CSPC PHARMACEUT.GR. ADR4 Cash Flow Quality Index by Year (2021–2025)
CSPC PHARMACEUT.GR. ADR4 cash flow quality index by year from 2021 to 2025. Year-by-year earnings quality comparison for CSPC PHARMACEUT.GR. ADR4. For the full cash flow conversion analysis, see CSPC PHARMACEUT.GR. ADR4 cash conversion from operations.
| Year | Quality Index | Operating CF (EUR) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 1.50x | €5.83 Billion | €3.88 Billion | ▲ +53.4% |
| 2024 | 0.98x | €4.53 Billion | €4.63 Billion | ▲ +49.5% |
| 2023 | 0.65x | €4.18 Billion | €6.38 Billion | ▼ -40.3% |
| 2022 | 1.10x | €7.63 Billion | €6.95 Billion | ▲ +63.4% |
| 2021 | 0.67x | €4.64 Billion | €6.90 Billion | — |